Your recollection is correct.
From the 19 June 2000 Sheba webinar transcript ASX announcement.
Prof. Borje: "There were also two patients who were allowed to enter the treatment with active disease with CNS involvement: one with eye involvement and one with leptomeningeal or central nervous system involvement, both of them achieved a partial remission."
These are AML metasteses, not diseases of the CNS like Parkinsons Disease. But the partial responses do suggest that bisantrene may cross the blood-brain barrier.
(CNS = Central Nervous System, including the brain.)
The RAC 3-Pillar Trifecta, page-172
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.055(3.62%) |
Mkt cap ! $268.4M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.61 | $1.56 | $106.0K | 67.13K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 649 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 3000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |